Seven Steps For Allogeneic Cell Therapy Success

By John Lee, VP, Head of Cell Therapy Manufacturing, Patricia Lindler, Associate Director, Cell Therapy Manufacturing, David Aponte Jr., Associate Director, Cell Therapy Manufacturing, and Tatiana Nanda, Head of Cell & Gene Therapies Drug Product Development

Allogeneic, or "donor-derived," CAR T cells have the potential to broaden access to treatment for patients. To prepare for commercial scale, companies must think through a number of considerations around scale-up, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics.

In this white paper, experts explore these topics to adapt lessons learned from autologous manufacturing.